Ati Joint And Bone Meds (Ra Drugs)

Front 1

immunosupressant med:
methotrexate (Rheumatrex)
leflunomide (Arava)

Back 1

DMARDS I major nonbiologic

Front 2

antimalarial agents:
hydroxychloroquine (Plaquenil)

Back 2

DMARDS I

Front 3

antiinflammatory: sulfasalzaine (Azulfidine)

Back 3

DMARDS 1

Front 4

tetracycline antibiotic
minocycline (Minocin)

Back 4

DMARD 1

Front 5

tumor necrosis factor antagonists
etanercept (Enbrel)
infliximab (Remicade)
adalimumab (Humira)

Back 5

DMARD II major biologic

Front 6

B lymphocyte depleting agent
rituximab (Rituxan)

Back 6

DMARD II

Front 7

interleukin 1 receptor agonist
abatacept (Orencia)

Back 7

DMARD II

Front 8

gold salts: auranofin (Ridaura)

Back 8

DMARDS III minor, nonbiologic and biologic DMARDS

Front 9

penicillamine (c=Cuprimine, Depen)

Back 9

DMARDS III

Front 10

immunosuppressant meds: azathioprine (Imuran), cyclosporine (Sandimmune, Gengraf, Neoral)

Back 10

DMARDS III

Front 11

glucocorticoids

Back 11

prednisone (Deltasone)
prednisolone (Prelone)

Front 12

NSAIDS

Back 12

aspirin
ibuprofen (Motrin, ADvil)
diclofenac (Voltaren)
Indomethacin (Indocin)
Meloxicam (Mobic)
Naproxin (Naprosyn)
celexicob (Celebrex)

Front 13

DMARDS MOA

Back 13

slow joint degeneration and progression of RA

Front 14

glucocorticoid MOA

Back 14

provide symptomatic relief of inflammation and pain

Front 15

NSAIDS MOA

Back 15

provide rapid, symptomatic relief of inflammation and pain

Front 16

RA meds Use

Back 16

analgesia for pain, swelling, joint tenderness
maintenance of joint function
slow/delay worsening of disease
short-term therapy until long-acting DMARDS take effect (NSAIDS, glucocoricoids)
prevention of organ rejection in transplant clients such as kidney, liver, and heart transplants (glucocorticoids, immunosupressants)
management of inflammatory bowel disease (glucocorticoids, immunosuppressants, DMARDS)

Front 17

methotrexate adverse

Back 17

increased risk of infection
hepatic fibrosis
bone marrow supression
ulcerative stomatis, GI effects
fetal death, congential abnormalities

Front 18

gold salts (Auranofin) adverse

Back 18

toxicity
renal toxicity (proteinuria)
blood dyscrasias
hepatitis
GI discomfort

Front 19

sulfsalazine adverse

Back 19

GI discomfort
hepatic dysfunction
bone marrow suppression

Front 20

antimalarial hydroxychloroquine adverse

Back 20

retinal damage

Front 21

tumor necrosis factor antagonist: etanercept, infliximab adverse

Back 21

injection site irritation
IV infusion reactions
risk of infection
severe skin reactions
HF
blood dyscrasias

Front 22

penicillamine adverse

Back 22

bone marrow supression
toxicity

Front 23

cyclosporine adverse

Back 23

risk of infection
hepatotoxicity
nephrotoxicity
hirsutism

Front 24

glucocorticoids: prednisone

Back 24

risk of infection
osteoporosis
adrenal supression
fluid retention
GI discomfort
hyperglycemia
hypokalemia

Front 25

methotrexate contraindications

Back 25

liver failure, alcoholism, blood dyscrasias
supressed bone marrow function, PUD, UC, impaired nutritional status, or infection
caution: children and older adults

Front 26

etanercept (Enbrel) contraindications

Back 26

malignancies, active infection, hematologic disorder
lactation
Caution: HF, CNS demyelinating disorders such as MS or blood dyscrasias

Front 27

cyclosporine contraindications

Back 27

pregnancy, recent vaccination with live virus vaccines, recent contact with or active infection of chicken pox or herpes zoster

Front 28

glucorticoid contraindications

Back 28

systemic fungal infections
live virus vaccines
do not abruptly discontinue glucocorticoids

Front 29

methotrexate interactions

Back 29

salicylates, other NSAIDS, sulfanomides, penicillin, tetracyclines may cause methotrexate toxicity
folic acid decreases effect

Front 30

entanercept interactions

Back 30

live vaccine
immunosuppressants

Front 31

cyclosporine interactions

Back 31

phenytoin, phenobarbital, rifampin, carbamazepine and trimethoprim-sulfamethoxazole decreases level which can lead to organ rejection
ketoconazole, erythromycin, amphotericin B may lead to toxicity
amphotericin B, aminoglycoside, and NSAIDS are nephrotoxic
concurrent use with cyclosporine increases risk for kidney dysfunction
grapefruit juice increases cyclosporine levels which poses increased risk of toxicity

Front 32

glucocorticoids interactions

Back 32

promote potassium loss increase the risk of hypokalemia
digoxin- increased risk of dysrythmias
NSAIDs- GI ulceration
oral hypoglycemics and insulin- glucocorticoids promote hyperglycemia